The Company is currently developing a range of pharmaceutical product projects that are mostly based on its Multi Matrix MMX® technology. This technology allows the delivery of active pharmaceutical ingredients mainly into the lumen of the colon through tablet erosion in a delayed and controlled manner. This has the effect that the active pharmaceutical ingredients can be applied to the full length of the colon.
The Company's proprietary clinical development pipeline specifically addresses innovative treatments for Colon Diseases, with the group's first product Lialda® launched in the US and EU, with the nutraceutical Zacol NMX® launched for the local market in Italy and in selected Eastern European countries and with UCERIS® launched in the US and Cortiment® to be launched in the Netherlands. In addition, one product is in Phase III, another about to start phase III, one in Phase II, and one is in phase Phase I. The Company has one new chemical entity, an anti androgen directed at topical skin diseases such as acne, hirsutism and alopecia that is in Phase II for acne and phase I for alopecia.
Cosmo has developed and is working on the following compound pharmaceutical products and nutraceuticals: